capecitabine has been researched along with Hemolytic-Uremic Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahlgren, J; Akin, E; Bishop, C; Guebre-Xabiher, H; Kirkel, D; Patel, N; Schuck, S; Siegel, P; Siegel, R; Simmens, S | 1 |
| Arce-Lara, C; Bekaii-Saab, T; Cataland, S; Kraut, E; Ntukidem, N; Otterson, GA | 1 |
1 review(s) available for capecitabine and Hemolytic-Uremic Syndrome
| Article | Year |
|---|---|
Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Hemolytic-Uremic Syndrome; Humans; Irinotecan; Mitomycin; Prospective Studies; Purpura, Thrombotic Thrombocytopenic | 2010 |
1 other study(ies) available for capecitabine and Hemolytic-Uremic Syndrome
| Article | Year |
|---|---|
O-MAX chemotherapy: high activity in metastatic esophagogastric adenocarcinoma and possible relation to subclinical hemolysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Haptoglobins; Hematologic Diseases; Hemolytic-Uremic Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Stomach Neoplasms; Treatment Outcome | 2014 |